2 Fast-Growing Pharmaceutical Stocks to Buy Now
Yahoo Finance ·
Incyte ( INCY 0.67% ) and TG Therapeutics ( TGTX 1.43% ) are commercial-stage biotech companies that are using blockbuster drugs to fund the growth of their promising pipelines. Incyte is known for its work in Janus kinase (JAK) inhibition, focusing on dermatology, oncology, hematology, inflammation, and autoimmune disorders . TG Therapeutics is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Both stocks are delivering strong returns. Shares of Incyte are up more than 17% this year, while TG Therapeutics is up nearly 90% so far in 2026. Here are reasons to buy the pharmaceutical stocks: Incyte's financial health is anchored by its blockbuster JAK inhibitor, Jakafi, for rare blood cancers, and its fast-growing dermatology cream, Opzelura, approved to treat vitiligo and eczema.
DYAX Investor Sentiment
Bullish (Long) 58% · Bearish (Short) 42%
395 participants
Related News
- Levi Strauss raises FY2026 outlook to 7%-7.5% reported revenue growth and $1.46-$1.52 EPS while expanding DTC-first model
- Why Kingsoft Cloud Holdings Stock Jumped Today
- Commvault (CVLT) Stock Has Cheap Cash Flow But Expensive Earnings
- Why Broadcom Stock Fell 15% in June
- PRE-MARKET TAIWAN AND SINGAPOREAN STOCK NEWS: CSBC to expand maritime forces, Temasek's sustainable living portfolio rises 7% Y/Y
- Apple scores record 89 Emmy Award nominations, with top category nods for celebrated comedies Widow’s Bay, Shrinking, and Margo’s Got Money Troubles, and global hit dramas Pluribus, Slow Horses, and Your Friends & Neighbors